Shosuke Imai

TL;DR: Phage therapy will compensate for unavoidable complications of chemotherapy such as the appearance of multidrug resistance or substituted microbism, and phage-coded inhibitors of peptidoglycan synthesis (protein antibiotics), search methods for novel antibacterial agents using phage genome informatics, and vaccines utilizing phages or their products are being developed.

TL;DR: It is reported that EBER induces signaling from the Toll-like receptor 3 (TLR3), which is a sensor of viral double-stranded RNA (dsRNA) and induces type I IFN and proinflammatory cytokines and EBER-induced activation of innate immunity would account for immunopathologic diseases caused by active EBV infection.

TL;DR: Guidelines, derived mainly from the current literature and recent experiences with CAEBV in Japan, for diagnosing CA EBV are proposed to clarify this enigmatic disease.

TL;DR: Multivariate analysis revealed that thromobocytopenia and age at disease onset were correlated with mortality, and patients with CAEBV with late onset of disease, thrombocy topenia, and T cell infection had significantly poorer outcomes.

TL;DR: It is suggested that oral administration of phage may be effective against gut-derived sepsis caused by P. aeruginosa, and the levels of inflammatory cytokines in blood and liver were significantly lower inphage-treated mice than in phage-untreated mice.